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Michael T White1* and David L Smith2,3Abstract
Plasmodium falciparum infections present novel challenges for vaccine development, including parasite replication
dynamics not previously encountered for viral pathogens, and enormous diversity in target antigens. These
challenges are illustrated by using a mathematical model to describe the association between the proportion of
pre-erythrocytic or blood-stage parasites eliminated by vaccine-induced immune responses and the proportion of
infections prevented. It is hypothesized that due to the requirement for all sporozoites to be eliminated to prevent
infection, combining infection-blocking vaccines that confer protection through different biological mechanisms
could lead to synergistic combinations of efficacy. Vaccines targeting blood-stage parasites may also combine
synergistically if they combine to reduce the parasite multiplication rate to below the threshold of 1.
Keywords: Malaria, Vaccine, Infection, Pre-erythrocytic, SynergyBackground
Plasmodium falciparum infections present novel chal-
lenges for vaccine development, including parasite repli-
cation dynamics not previously encountered for viruses,
and enormous diversity in target antigens [1]. Malaria
parasites express multiple life stages in humans, each
presenting unique targets for vaccine-induced immune
responses. Malaria infection can be prevented either by
targeting the pre-erythrocytic (PE) stages and clearing
sporozoites inoculated in the skin or infected hepato-
cytes in the liver, or by targeting blood-stage (BS) mero-
zoites and infected red blood cells in the prepatent
period after emergence from the liver and before para-
site densities increase to detectable levels. The dynamics
of these parasite life stages and corresponding immune
kinetics also differ. Sporozoites pass from the skin to the
liver without replicating, so clearing sporozoites or elim-
inating hepatocytes can prevent infection outright. The
pass-through system also means that the immune sys-
tem will be naturally exposed to and stimulated by rela-
tively few sporozoites, but this number increases after
repeated exposure to infectious bites of mosquitoes. BS
parasites undergo periodic replication, so like viral* Correspondence: m.white08@imperial.ac.uk
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distribution, and reproduction in any mediumpathogens, the combined vaccine-induced and naturally
acquired immune response can prevent infection if
enough parasites are cleared so that the number of para-
sites is reduced from one generation to the next. Repli-
cation of BS parasites implies that the immune system
will be exposed to very high parasite numbers from a
single infection.
The sporozoite bottleneck would seem to make an
easy vaccine target, but the potential for a single parasite
to evade vaccine-induced immune responses and spark
an infection makes the challenge of developing an effect-
ive PE vaccine deceptively difficult. The effect of BS mal-
aria vaccines on BS parasites is qualitatively similar to
successful vaccines against viruses, in that a threshold
immunological correlate for sterile protection against in-
fection is theoretically possible. Hepatic parasites that
survive the PE immune response will release merozoites
into the blood stream which invade and replicate within
red blood cells, causing an increase in parasite numbers
every two-day cycle by a factor defined as the parasite
multiplication rate (PMR) [2]. PMR >1 will lead to an
increase in parasite numbers and possibly an episode of
clinical malaria, and PMR <1 will lead to a decrease in
parasite numbers and the clearance of BS infection. BS
vaccines prevent the replication of BS parasites by either
preventing merozoites from invading red blood cells or
clearing infected red blood cells. A BS vaccine that failsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ical and severe episodes by providing time for the natural
immune response to mature. In a study in Aotus monkeys,
a reduction in median PMR from 15 to 5 in the early
phase of infection was associated with subsequent clear-
ance of parasites without developing symptoms of
anaemia (Sandy Douglas – personal communication). In
contrast to BS vaccines, which need not clear every para-
site, PE vaccines must prevent the successful development
of each sporozoite, a challenging prospect given that most
evidence suggests that the number of sporozoites inocu-
lated per infectious bite is highly skewed, with some bites
injecting very large numbers of sporozoites [3].
The potential benefits of multicomponent malaria
vaccines
Although both PE and BS vaccines induce immune
responses that target individual parasites within the hu-
man host, the relationship between the average propor-
tion of parasites killed and the proportion of infections
prevented (efficacy against infection) is qualitatively differ-
ent, as illustrated in Figure 1. Given that a single sporozo-
ite evading the vaccine-induced immune response isFigure 1 Estimated efficacy against infection as a function of the ave
and blood-stage vaccines (red). (a) The number of successfully developin
with mean n and shape parameter r = 0.5. With a mean of n = 30 sporozo
prevent 20% of infections. Combining two vaccines that eliminate 85% of s
multicomponent vaccine that prevents 60% of infections. The curve is conv
eliminated translate to greater increases in efficacy against infection. (b) Blo
cycle by a factor equal to the parasite multiplication rate (PMR), which varie
coefficient of variation Cv = 0.5. With a mean PMR = 8, a blood-stage vacci
Combining two vaccines that eliminate 75% of parasites through independ
95% of infections. The point of inflection in the curve corresponds to the p
below the threshold of 1.sufficient to initiate malaria infection, and that during
some mosquito bites large numbers of sporozoites may be
inoculated, it is not predicted that there will be any
threshold immunological correlate of protection at which
sterile protection from infection is conferred, and hence
that pre-erythrocytic malaria vaccines will be leaky [4].
This could explain, in part, why RTS,S has produced such
high antibody responses, yet estimates of efficacy against
infection are approximately 50% [5]. The convex shape of
the curve for PE vaccines in Figure 1a suggests that
preventing 50% of infections requires that, on average, in
excess of 90% of sporozoites be killed [6]. The steepness
of the curve in this region implies that incremental
improvements in the proportion of parasites killed
can lead to substantial improvements in efficacy against
infection as the last few sporozoites are cleared up. An
implication of this is that if two PE vaccines providing
protection through different biological mechanisms are
co-administered, efficacies are expected to combine syner-
gistically. For example, if two vaccines kill 85% of sporozo-
ites and prevent 20% of infections when administered on
their own, they will kill 1 - (1–0.85)2 ≈ 98% of sporozoites
when combined, but prevent approximately 60% ofrage proportion of parasites killed for pre-erythrocytic (green)
g sporozoites is assumed to follow a Negative Binomial distribution
ites, a pre-erythrocytic vaccine that eliminates 85% of sporozoites will
porozoites via independent mechanisms will result in a
ex such that incremental increases in the proportion of sporozoites
od-stage parasites are assumed to increase in number every two-day
s among individuals according to a Log-Normal distribution with
ne that eliminates 75% of parasites will prevent only 10% of infections.
ent mechanisms will result in a multi-component vaccine preventing
roportion of BS parasites that must be eliminated to reduce the PMR
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combination of two BS vaccines, but this depends on
whether the combined effect of the two vaccines is suffi-
cient to reduce the PMR below the threshold of 1 in a
large proportion of the vaccinated cohort. The threshold
proportion of BS parasites killed to prevent infection cor-
responds to the inflection point of the curve in Figure 1b.
The challenge to vaccine developers in selecting an
antigen to effectively target, may be turned into an op-
portunity to target multiple antigens [7] with efficacy
combining synergistically. Synergy will depend not just
on the initial efficacy after vaccination, but on the dur-
ation of each component vaccine, with waning driven by
the vaccine with the shortest half-life.
Combining existing vaccines may lead to synergistic
improvements in efficacy
RTS,S has been shown to prevent approximately 50% of
infections by eliminating >95% of sporozoites [8]. It is
hypothesized that, due to the requirement for all sporo-
zoites to be eliminated to prevent infection, combining
RTS,S with a second vaccine that targets sporozoites via
a different mechanism could lead to a multicomponent
vaccine that prevents substantially more than 50% of in-
fections. This would hold even if the second vaccine has
negligible efficacy against infection when administered
on its own, so long as it eliminates sufficient numbers of
sporozoites [9], and there is no immunological interfer-
ence between the two vaccines [10]. This phenomenon
may also explain the high levels of efficacy against infec-
tion following immunization by irradiated sporozoites
[11] which may confer protection by simultaneously
inducing multiple, independent immune responses di-
rected towards P. falciparum sporozoites.Competing interests
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